Dizhe Pharmaceutical: Dizhe Pharmaceutical: Voluntary Disclosure Notice on Schwarzhe\'s First-Line Treatment for Advanced Non-Small Cell Lung Cancer with EGFR 20 Exon Insertion Mutation Obtaining CDE Breakthrough Treatment
Digel Pharmaceutical Investor Relations Activity Record Table_2024 Semi-Annual Science and Technology Innovation Board Pharmaceutical and Biological Products Group Performance Briefing
Digel Pharmaceuticals Investor Relations Activity Record List_August-September 2024
Digel Pharmaceuticals: Dizhe Pharmaceutical: Voluntary Disclosure of the Report on Schwarzhe\'s Globally Registered Clinical Research Subgroup Data Selected for the 2024 European Society of Medical Oncology (ESMO) Conference
Dizhe Pharmaceutical: Huatai United Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Digi (Jiangsu) Pharmaceutical Co., Ltd.
Dizhe Pharmaceutical: Announcement on participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Dizhe Pharmaceutical: Announcement of Resolutions of the Seventh Meeting of the 2nd Board of Supervisors
Dizhe Pharmaceutical: Special Report on the Storage and Actual Use of Funds Raised for the 2024 Semi-Annual Year
Dizhe Pharmaceutical: Semi-annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Value Return” Action Plan
Dizhe Pharmaceutical: Announcement of Resolutions of the Eighth Meeting of the 2nd Board of Directors
Dizhe Pharmaceutical: Report on the use of previously raised funds
Dizhe Pharmaceutical: Announcement on the change of accounting firm
Dighe (Jiangsu) Pharmaceutical Co., Ltd. Investor Relations Activity Record Form from April to May 2024
Digel Pharmaceutical Investor Relations Activity Record Table_2023 Pharmaceutical Special Group Performance Briefing
Dizal: Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Performance Briefing
Dizal: Huatai United Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Dighe (Jiangsu) Pharmaceutical Co., Ltd.
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Report and Verification Report on the Use of Funds Raised by Digee (Jiangsu) Pharmaceutical Co., Ltd. as of December 31, 2023
Dizal: 2023 Financial Statements and Audit Report
Dizal: Report on the use of previously raised funds
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Special Report on the Capital Occupation by the Controlling Shareholders and Other Related Parties of Digee (Jiangsu) Pharmaceutical Co., Ltd. in 2023
No Data
No Data